Recent history demonstrates that vaccination of children to prevent future disease can induce an often-acrimonious debate.
disease and a relatively simple treatment to prevent disease progression. However, cervical screening is not completely benign. Women may find screening and treatment of CIN distressing, and LLETZ can affect future pregnancy outcomes by increasing the risk of late miscarriage and premature delivery. [6] [7] [8] The aetiology of cervical cancer and the natural history of its development are well understood. [9] High-risk types of HPV are the main cause of almost all cervical cancers, with HPV types 16 and 18 together responsible for 70% of cervical cancer worldwide. [10] Although almost everyone will be exposed to HPV, most will clear the virus through an immune response within six to 18 months. In a minority of women, the virus infection is not cleared, and they can go on to develop CIN and then cervical cancer over several years.
HPV is a DNA virus, made up of a protein shell (capsid) containing viral DNA. The proteins that make up the capsid, when produced artificially, self-assemble into empty capsids, forming viruslike particles (VLPs).
[11] VLPs do not contain viral DNA and so cannot cause an active infection. VLPs stimulate an immune response, producing antibodies that bind to the virus shell, blocking the receptors that mediate infection. By priming the immune system with VLPs, the body is able to mount a more robust response to subsequent natural exposure to HPV, thereby reducing the likelihood of infection and its consequences. Vaccines have been developed based on combinations of VLPs for HPV types 16 and 18, plus types 6 and 11 (which cause genital warts), or newer combinations of up to nine different VLPs.
Cervical cancer can take many years to develop following the initial HPV infection, so waiting to see to what extent HPV vaccines could reduce cancer rates would take several decades and involve trials of millions of women. Reduction of development of high-grade CIN is therefore thought to be a valid, medium-term outcome that will predict whether vaccination can reduce cervical cancer rates.
[12] Furthermore, reduction in CIN rates alone could lead to clinically meaningful outcomes, reducing pain, distress, and poor obstetric outcomes.
In their Cochrane Review, Arbyn and his team have combined the results of 26 randomized control trials of HPV vaccination to prevent cervical cancer. [2] These trials included 73,428 women and adolescent girls, across a variety of populations. The authors looked separately at the effects of vaccination in those who at baseline had no evidence of HPV DNA, HPV 16/18 specifically, or participants unselected for baseline DNA status. They also looked at whether the results of studies done in younger women (aged under 26 years of age) differed from those in older women (aged 24 to 45 years).
The results for women known to be negative for HPV16/18 are interesting in a research context and tell us that HPV vaccines reduce high-grade CIN caused specifically by HPV16/18 in younger women from 113 to 6 per 10,000 women. This would mean that we need to vaccinate about 62 young women who are known to be free of HPV16/18 for one to be protected against high-grade cervical lesions. However, in a real-world setting it is unlikely that HPV testing would be performed prior to vaccination. In adolescent girls and young women (15 to 26 years) who were unselected on the basis of HPV exposure, vaccination reduced high-grade CIN caused specifically by HPV16/18 from 341 to 157 per 10,000 women, and any high-grade CIN from 559 to 391 per 10,000 women. The corresponding numbers needed to vaccinate for these outcomes are 54 and 68, respectively.
In women aged over 24 years (the population most likely to have already been exposed to HPV) the vaccines do not confer similar benefits. The risk of any high-grade CIN is similar between unvaccinated and vaccinated older women, although CIN caused specifically by HPV 16/18 is probably slightly lower following HPV vaccination.
Follow-up periods in the studies in the review ranged between 1 and 8.5 years, with most around 3 to 5 years. Over time, the vaccine may have even more of an effect in those not exposed prior to vaccination, since high-grade CIN can take several years to develop following initial HPV exposure.
While we can be confident that rates of serious adverse events and miscarriage are similar between vaccinated and unvaccinated women, other rare harms are difficult to determine in randomized controlled trials, even those that have recruited tens of thousands of participants. We now need to look to follow-up of registry data involving millions of women to assess any relationship between vaccination and autoimmune conditions.
The data indicate that HPV vaccination is most effective in those not already exposed to HPV, supporting the widespread introduction of vaccination programmes aimed at young adolescent girls. Catch-up vaccination programmes in older girls and young women will have less of a benefit, based on these data. Importantly, some harms of vaccination are likely to be detected over a relatively short period, compared with harms from other medicines, and all but very rare harms would be captured during large randomized controlled trials. A more complete picture of the beneficial effects on CIN and pregnancy outcomes is only likely to be realized over the course of many years. In the case of cervical cancer, the true effects will probably not be evident for one to two decades. This Cochrane Review answers some important questions with high certainty of evidence. Some questions cannot be answered by this review, including effects on very rare side effects, vaccination of boys, and other, longer-term HPV-related cancer outcomes. HPV is known to increase the risk of other cancers, such as vulval and penile cancers, and some head and neck cancers. Such cancers are rarer and take longer to develop. Ascertaining effects of vaccination on these rarer outcomes may require the evaluation of non-randomized, population-level evidence over many years.
Cochrane aims to evaluate and present the evidence to decision-makers, be they governments, healthcare policy makers, parents, or young women. We hope that this review will be used to support policy or personal decision-making about HPV vaccination that is informed by the best current evidence, balancing facts rather than opinions. 
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Provenance and peer review
This editorial was commissioned and was not externally peer reviewed. There are other major biases and mistakes in the review which we have described elsewhere (4) and have addressed in other submitted publications, but for the purpose of this complaint it is sufficient for you to note that the presence of a sizeable number of trials that the authors did not include was flagged up many months prior to publication and ignored by authors, review group and Editorial Unit.
Image credit
The editorial may breach the spokesperson policy. The editorial states "We hope that this review [Arbyn] will be used to support policy or personal decision-making about HPV vaccination that is informed by the best current evidence, balancing facts rather than opinions" Ever since I have been involved in Cochrane we specifically avoid making any statements on policy. That is not our job. Here we have statements on both personal and general policies. Given the visibility and the role of the authors this seems to infringe the spokesperson policy statement "we can protect against this by clarifying when we are speaking on Cochrane's behalf or in a personal capacity". The policy suggests two ways of doing this. By saying (or writing) "in my opinion…" or adding a statement such as "The views expressed are my opinions and not the expressed views of any organization to which I am affiliated." No such disclaimers or qualifiers were visible in the editorial, leaving readers to assume the statements represented the views of Cochrane.
The editorial states that "all but very rare harms would be captured during large randomized controlled trials." This is misleading, as not a single trial included in the Arbyn review had a control group where participants were treated with a placebo. They all received a hepatitis vaccine or the adjuvant, and if these cause similar harms as the HPV vaccines, such harms would be overlooked in the trials.
It is unclear to me on what basis editorials are commissioned, by whom, whether they are peer reviewed or not and what is the criterion for preferring an editorial to a humble blog and how the degree of press releasing is decided.
Finally it would be good to know how the six "experts" interviewed in the press release were selected (5). Their gushing statements and the content of the Arbyn et al review are not based on any serious effort to assess the evidence. Collectively, the Review, Editorial, and the press release create the impression that there was an overarching strategy behind their publication to send a political message. This would be counter to the fundamental purposes of the Cochrane Collaboration.
I look forward to hearing from you and would be grateful for an acknowledgment of this letter. Should we screen women for abdominal aortic aneurysm?
In The Lancet, Michael Sweeting and colleagues 1 report their estimate of the benefits, harms, and costeffectiveness of screening women for abdominal aortic aneurysm (AAA) based upon their modelling study. A discrete event simulation model was set up and womenspecific parameters were obtained from systematic literature reviews, national registry or administrative databases, major AAA surgery trials, and UK National Health Service reference costs. By use of the same screening strategy as used for men (age 65 years; 3·0 cm cutoff for diagnosis; 5·5 cm cutoff for surgery), there were three fewer AAA-related deaths, ten women overdiagnosed with AAA, and one woman overtreated for AAA per 10 000 invited over a 30-year period. For every four women who avoided an AAA-related death, one died because of additional elective repair as an outcome of screening. The authors conclude that this screening is not cost-effective. In the authors' best-alternative strategy (including women aged 70 years; 2·5 cm cutoff for diagnosis; 5·0 cm cutoff for surgery), screening resulted in six fewer AAA-related deaths, 67 women overdiagnosed with AAA, and five women overtreated for AAA for every 10 000 women invited over a 30-year period. For every seven women who avoided an AAA-related death, two died because of additional elective repair as an outcome of screening. It is unusual for cost-effectiveness analyses of screening to include overdiagnosis and overtreatment. This study is therefore an important step forward. However, there was considerable uncertainty regarding the cost-effectiveness (incremental costeffectiveness ratio of £23 000 per quality-adjusted life-year [QALY] for the best-alternative strategy; 95% CI 9500-71 000), mainly because of assumptions about AAA prevalence, distribution of aortic size at different ages, and effects on quality of life. Sensitivity analyses showed that a negative effect on quality of life as a result of diagnosis, including overdiagnosis, would substantially reduce cost-effectiveness. This association has been poorly investigated for most screening programmes. Therefore, this finding could challenge the continued justification of screening for many other diseases, 2 making the effects of screening on quality of life a high-priority research area.
Assumptions about future reductions in disease prevalence also substantially reduced cost-effectiveness.
Previous studies have shown decreasing AAA-related mortality in women from the mid-1990s to 2009. 3 In 1974, 41% of UK women smoked compared with 17% in 2014, 4 and since the correlation between smoking and AAA is stronger in women than in men, AAA-related mortality is likely to continue to decrease for women, reducing the need for screening.
Apart from concerns about cost-effectiveness, there are ethical dilemmas associated with the use of AAA screening. That the health-care system causes the death of healthy citizens by inviting them to an intervention that they have not asked for is ethically problematic. It is not as simple as a matter of net benefit in terms of mortality because it is not clear that a death saved by screening equals out a death caused by screening-such strict utilitarianism is hardly acceptable.
Furthermore, there are other important harms. The best-alternative strategy in the study by Sweeting and colleagues resulted in a 55% increase in women who fulfilled criteria for elective surgery for AAA but had contraindications. They were told that they have a condition that could cause death at any minute but that nothing can be done for them since any elective procedure would be too risky.
Elective surgery for AAA has serious complications such as myocardial infarction, stroke, amputation, respiratory failure, renal failure, ischaemic colitis, spinal cord ischaemia, and prosthetic graft infections. 5, 6 Screening results in a large increase in elective surgeries during the
